

First Quarter 2011 Earnings Release






☐ Dial toll-free: 800.642.1687

**☐** International: 706.645.9291

☐ Conference ID: #56253366

☐ Log on to: www.idexcorp.com



Cautionary Statement
Under the Private Securities

**Litigation Reform Act** 

This presentation and discussion will include forward-looking statements. Our actual performance may differ materially from that indicated or suggested by any such statements. There are a number of factors that could cause those differences, including those presented in our most recent annual report and other company filings with the SEC.



- ☐ Strategy continues to pay off
  - Strong global growth
  - Niche markets with a great growth model
- **☐** Productivity initiatives help drive bottom line performance
  - Operational Excellence
- □ Pricing offsetting inflation
  - Positive price
  - Global Sourcing
- Opportunities to deploy capital




Chem / Industrial			
+ Chemical production up in Europe			
+ Chem / Industrial investments in China			
+ HST Industrial, Band clamping, other Ind. strong			
± U.S. expansion modest / MRO continues			
Life Science / Analytical Instrumentation			
+ Global growth outstanding			
Fire & Rescue			
+ Rescue International growth			
<ul> <li>US Muni – Pumper truck builds still weak</li> </ul>			
Water			
+ International growth			
<ul> <li>US Muni continues to struggle</li> </ul>			
Energy			
+ Global growth; mid and downstream			
Paints			
+ International growthE. Europe and Asia			
<ul> <li>U.S. soft but stable</li> </ul>			
Agriculture			
+ OEM and aftermarket very strong			
Pharma			
+ Both big Pharma and generic			


Served Market	% of Total IDEX
Chem / Industrial	30%
A.I. / Life Sciences	17%
Fire & Rescue	13%
Water	11%
Energy	10%
Paints	7%
Agriculture	4%
Pharma	4%
Other	4%




## **Total Revenue**




#### **EPS**



# **Operating Margin**




## **Free Cash Flow**




2010 EPS / Op Margin data adjusted for restructuring expense









#### **Total Revenue**



#### **Operating Margin**





#### Q1 Summary:

- □ Strong top line growth; executing organic growth initiatives
- ☐ Energy, Chemical, Agriculture very strong globally
- ☐ Water/Waste Water ok globally, challenged with US muni spend
- ☐ Margin expansion; productivity / price offsetting inflation









Organic	+19%
Acquisition	+24%
Fx	Ξ
Total	+43%
	Acquisition Fx

**Q1 Summary**:

- ☐ New products and increased content within L.S. and A.I.
- ☐ Industrial, environmental, and medical strong
- ☐ Optics and Seals PPE® performing very well
- ☐ Completed Microfluidics and AT Films acquisition
- ☐ Completed segment transfer of Pharma platform from FMT to HST; better fit from a market perspective





Q1 Sales Mix:	Organic	-5%	Q1 Summary:
	Acquisition	_	☐ Wins in Eastern Europe and Asia
	Acquisition		☐ Latin America markets performing well
	Fx	<u>+1%</u>	☐ Holding share in N.A.; wins on retrofits and spare parts
	Total	-4%	☐ Nearly 18% op margin reflects right-sized cost structure









Q1 Sales Mix:	Organic	+4%
	Acquisition	-
	Fx	+1%
	Total	+5%

#### Q1 Summary:

- ☐ Rescue winning internationally; China PLA win
- ☐ Rescue North America challenged but winning with eDraulic
- ☐ BAND IT growth exceeding expectations; O&G, new applications
- ☐ North American Fire markets not improving, Int'l share growing



## **Outlook: 2011 Guidance Summary**

#### **Q2 2011**

- **☐** EPS estimate range: \$0.58 \$0.60
  - Organic revenue growth of 7% 8%
  - ➤ Positive Fx impact of ~3% to sales (at Mar 31 rates)
  - **→** Positive impact of 4-5% from acquisitions

#### **FY 2011**

- **□** EPS estimate range: \$2.30 \$2.40
  - Organic revenue growth in the high single digits
  - > Operating margin of 18.0% 18.5%
  - ➢ Positive Fx impact of ~2% to sales (at Mar 31 rates)
  - **▶** Positive impact of ~4% from acquisitions
- **□** Other modeling items
  - > Tax rate = 32.5%
  - > Cap Ex \$34-36M
  - > Free Cash Flow will significantly exceed net income
  - > EPS estimate excludes future acquisitions and related costs



# Q&A

